Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

30 trials with published results (59%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 15/100

Termination Rate

11.8%

6 terminated out of 51 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

55%

28 trials in Phase 3/4

Results Transparency

71%

30 of 42 completed with results

Key Signals

30 with results88% success

Data Visualizations

Phase Distribution

47Total
Not Applicable (3)
Early P 1 (1)
P 1 (2)
P 2 (13)
P 3 (19)
P 4 (9)

Trial Status

Completed42
Terminated6
Recruiting1
Unknown1
Withdrawn1

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 42 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT03370133Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03598790Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03410992Phase 3CompletedPrimary

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03897075Phase 3CompletedPrimary

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

NCT03025542Phase 2CompletedPrimary

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT06011733Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

NCT07337434Early Phase 1RecruitingPrimary

To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital

NCT03982394CompletedPrimary

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT03766685Phase 3CompletedPrimary

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

NCT04286607Phase 3CompletedPrimary

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT00799877CompletedPrimary

Chronic Plaque Psoriasis (Ps) Registry

NCT00233662Phase 3CompletedPrimary

Safety and Tolerability of Repeat Courses of IM Alefacept

NCT04211363Phase 3CompletedPrimary

Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04211389Phase 3CompletedPrimary

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT03010527Phase 2CompletedPrimary

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03230292Phase 2CompletedPrimary

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

NCT02905006Phase 2CompletedPrimary

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT02852967Phase 2CompletedPrimary

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Scroll to load more

Research Network

Activity Timeline